IFNB1 and multiple sclerosis: The number of CD80+ lymphocytes in the blood increased significantly during the exacerbation of multiple sclerosis, and after IFN-β treatment, the number of CD80+ lymphocytes in the blood decreased significantly, which initially indicated that the number of CD80(+) cells may be an indicator of whether IFN-β treatment is effective (46).